Lanreotide
Somatostatin AnalogapprovedAlso known as: Somatuline, Somatuline Depot, Somatuline Autogel, BIM-23014
A long-acting synthetic somatostatin analog administered as a deep subcutaneous depot injection every 4 weeks for acromegaly and neuroendocrine tumors.
Overview
Lanreotide is a synthetic octapeptide analog of somatostatin, structurally related to octreotide but with distinct pharmacokinetic properties. Available as Somatuline Depot/Autogel, it is formulated as a supersaturated aqueous solution that forms a gel depot upon deep subcutaneous injection, providing sustained drug release over 4 weeks. Lanreotide binds preferentially to somatostatin receptor subtypes 2, 3, and 5. It is FDA-approved for acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. The CLARINET trial established its antiproliferative effects in non-functioning GEP-NETs, expanding its use beyond symptom management.
Mechanism of Action
Lanreotide mimics somatostatin with prolonged activity: (1) Binds SSTR2, SSTR3, and SSTR5, inhibiting GH, TSH, and GI hormone secretion; (2) Forms a gel depot at injection site providing sustained release over 28 days; (3) Inhibits tumor cell proliferation through SSTR2-mediated pathways; (4) Reduces splanchnic blood flow; (5) Suppresses pancreatic and GI hormone secretion; (6) Inhibits gallbladder contractility.
Molecular Formula
C54H69N11O10S2
Molecular Weight
1096.34 g/mol
Sequence
D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (cyclic disulfide)
Dosage Protocols
Dose Range
60mg – 120mg
Frequency
Every 4 weeks
Route
deep subcutaneous
Cycle Length
Ongoing
Start at 90mg every 4 weeks. Adjust to 60mg or 120mg based on GH/IGF-1 levels. Self-administration possible after training.
Source: FDA prescribing information
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
60mg, 90mg, or 120mg pre-filled syringe
Last Updated
2026-02
Brand Somatuline Depot. For acromegaly/neuroendocrine tumors. Very expensive. Insurance typically covers for approved indications.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Gallstones / Biliary sludge | moderate |
| Diarrhea | mild |
| Abdominal pain | mild |
| Injection site reactions | mild |
| Hyperglycemia | moderate |
Pros & Cons
Self-injectable pre-filled syringe format — no reconstitution required
Proven antiproliferative effects in GEP-NETs (CLARINET trial)
Once-monthly dosing provides convenient, sustained drug delivery
High rate of gallstone formation similar to octreotide
Can impair glucose tolerance in diabetic patients
Expensive long-term therapy
Research Studies
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
FDA-approved for acromegaly, GEP-NETs, and carcinoid syndrome. Prescription-only. Deep subcutaneous injection every 4 weeks.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
Collagen Peptides
Bioactive peptide fragments derived from hydrolyzed collagen protein that support skin elasticity, joint health, bone density, hair/nail growth, and gut lining integrity through stimulation of endogenous collagen synthesis.